Published in Blood on June 12, 2014
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res (2015) 0.82
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2015) 0.81
Modeling Disorders of Blood Coagulation in the Zebrafish. Curr Pathobiol Rep (2015) 0.80
Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther (2016) 0.79
Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. Clinics (Sao Paulo) (2016) 0.79
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther (2014) 0.77
The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management. Saudi Med J (2015) 0.75
Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vasc Health Risk Manag (2016) 0.75
Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vasc Health Risk Manag (2016) 0.75
Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence (2017) 0.75
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Natural history of venous thromboembolism. Circulation (2003) 3.67
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med (1999) 2.98
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Dabigatran and postmarketing reports of bleeding. N Engl J Med (2013) 2.15
Acutely injured patients on dabigatran. N Engl J Med (2011) 2.05
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol (2007) 1.93
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost (2014) 1.92
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost (2010) 1.67
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost (2008) 1.55
New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet (2013) 1.31
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost (2013) 1.15
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes (2013) 1.00
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ (2013) 0.85
Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol (2012) 0.84
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost (2013) 0.78